Seeking Alpha

Halozyme cut to EqualWeight at Barclays

  • Halozyme Therapeutics (HALO -3.9%) slips after being downgraded to EqualWeight at Barclays.
  • The firm cites concern over FDA approval for certain product lines, saying it believes that PH20 remains a commercially viable platform, but FDA concerns over antibodies to PH20 put a damper on the approvability of any blood product such as HyQ and Cinryze in combination with PH20.
  • Barclays thinks the overhang will likely limit the stock's upside potential - especially in light of the VPHM announcement.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs